Author ' s response to reviews Title : Gemcitabine versus gemcitabine based combination chemotherapy in advanced pancreatic cancer
نویسندگان
چکیده
منابع مشابه
Author ' s response to reviews Title : Gemcitabine based combination chemotherapy in advanced pancreatic cancer
Background: Recent meta-analyses have foundd a survival advantage withh
متن کاملS-1 and gemcitabine as an outpatient-based regimen in patients with advanced or metastatic pancreatic cancer.
OBJECTIVE The standard beneficial chemotherapy proved for patients with pancreatic cancer is a regimen containing gemcitabine. Novel oral fluoropyrimidine, S-1, can be added to gemcitabine to improve the efficacy of chemotherapy and to provide better convenience for patients. We aimed to evaluate the efficacy and safety of S-1 plus gemcitabine combination chemotherapy as a first-line treatment ...
متن کاملNab-paclitaxel: potential for the treatment of advanced pancreatic cancer
Advanced pancreatic adenocarcinoma is a deadly disease and is considered incurable. For the past two decades, gemcitabine remained the major chemotherapeutic drug with modest clinical benefit. Many chemotherapy and targeted agents were combined with gemcitabine but failed to demonstrate improvement in pancreatic cancer (PC) survival. Taxanes (paclitaxel, docetaxel) were introduced in the clinic...
متن کاملIs There a Standard of Care for the Management of Advanced Pancreatic Cancer?. Highlights from the Gastrointestinal Cancers
Despite advances in our understanding of the molecular and genetic basis of pancreatic cancer, the outcome for this disease remains dismal. Gemcitabine, the standard chemotherapy for pancreatic cancer, offers modest improvement of tumor-related symptoms and marginal advantage of survival. Many chemotherapeutic and targeted agents have been pitted against or combined with gemcitabine in randomiz...
متن کاملPancreatic cancer: highlights from the 42nd annual meeting of the American Society of Clinical Oncology, 2006.
Despite advances in our understanding of the molecular and genetic basis of pancreatic cancer, the disease remains a clinical challenge. Gemcitabine, the standard chemotherapy for pancreatic cancer, offers modest improvement of tumor-related symptoms and marginal advantage of survival. New approaches, alone and in combination with gemcitabine, are being developed to combat this cancer. Combinat...
متن کاملذخیره در منابع من
با ذخیره ی این منبع در منابع من، دسترسی به آن را برای استفاده های بعدی آسان تر کنید
عنوان ژورنال:
دوره شماره
صفحات -
تاریخ انتشار 2008